Healthcare Industry News: Ipsen
News Release - January 27, 2006
Innocoll Announces First Asian Distribution Agreement for CollaRx GENTAMICIN SURGICAL IMPLANT in Hong KongASHBURN, Va., Jan. 27 (HSMN NewsFeed) -- Innocoll, Inc. announced its sales and marketing subsidiary, Innocoll Pharmaceuticals Ltd., has recently signed a distribution agreement for its CollaRx GENTAMICIN SURGICAL IMPLANT in Hong Kong with Greyon Healthcare Company Ltd.
The product is indicated for the treatment and prevention of post-operative acquired infection. Innocoll, Inc. acquired the product rights from Essex Chemis AG, an affiliated company of Schering-Plough Corporation (NYSE: SGP ) and has since assumed all sales, marketing and distribution activities for the product.
Dr. Michael Myers, President and CEO of Innocoll, Inc., stated, "Since the acquisition of CollaRx GENTAMICIN SURGICAL IMPLANT last year, it has been our goal to expand its use beyond its original presence in the European market. We are pleased to announce the introduction of the product in the Asian market by our partner Greyon Healthcare Company Ltd."
The product was developed using Innocoll's proprietary collagen-based technology, CollaRx(TM), and has been approved in 49 countries. It is marketed under the following different trade names: (COLLATAMP® G, COLLATAMP® EG, SULMYCIN® IMPLANT, GARAMYCIN® SCHWAMM, DURACOL®, DURACOLL®, GENTACOL®, GENTACOLL®, GARACOL®, GARACOLL®, CRONOCOL®) in Europe, Central and South America and Africa.
About GENTAMICIN SURGICAL IMPLANT
GENTAMICIN SURGICAL IMPLANT is a biodegradable leave-behind implant impregnated with the broad spectrum aminoglycoside antibiotic, gentamicin, and is indicated as an adjunct to systemic antibiotic therapy for the treatment and prevention of post-surgical acquired infection in both hard and soft tissues. It is based on Innocoll's CollaRx(TM) technology, a proprietary collagen-based system which locally delivers a wide variety of drug products, and can be formulated for implantable or topical application as a lyophilized sponge or as a cast film.
About Innocoll, Inc.
Innocoll is a privately held, fully integrated, global, hospital specialty pharmaceutical company specializing in surgical and dermatological products. It develops and markets internationally a range of medical products using its proprietary collagen-based technologies, CollaRx(TM) and LiquiColl®. For more information, please visit http://www.innocoll.com. For product or pipeline information, please visit http://www.innocoll-pharma.com.
About Greyon Healthcare Co. Ltd.
Greyon, a Hong Kong-based company, specializes in sales & marketing of pharmaceutical & medical products in the Hong Kong market. The company founders have held longstanding sales and marketing management positions in the Chinese pharmaceutical market, for companies such as GlaxoSmithKline, Pfizer, Ipsen and Merck & Co., Inc.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.